TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE Russian patent published in 2018 - IPC G01N33/50 C12Q1/686 C12Q1/6886 

FIELD: biotechnology.

SUBSTANCE: invention relates to molecular biology, oncology and biotechnology. Test-system for the prediction of relapses in patients with uterine corpus cancer, based on the level of expression of the ESR1 gene, contains control mixtures and a mixture for the real-time PCR reaction comprising 1 mM dNTPs, 12.5 mM MgCl₂, 5-fold PCR-buffer with 5-fold dye EvaGreen Dye, DNA polymerase Thermus aquaticus in an amount of 5 U/mcl and highly specific oligonucleotide primers for genes ESR1 and ACTB.

EFFECT: invention provides a simple and accurate prediction of relapse in patients diagnosed with uterine corpus cancer without the use of expensive equipment, as well as high sensitivity and specificity.

1 cl, 1 tbl, 2 ex